Fanconi Anemia Drug Market
According to Intent Market Research, the Fanconi Anemia Drug Market is expected to grow from USD 0.2 Billion in 2023 at a CAGR of 19.5% to touch USD 0.6 Billion by 2030. The Fanconi Anemia Drug Market is dominated by key players such as Amgen Inc., AstraZeneca, Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics, CSL Behring, Fate Therapeutics, GlaxoSmithKline plc (GSK), Intellia Therapeutics, Inc., Novartis AG, Pfizer Inc., Rocket Pharmaceuticals, Inc. and Vertex Pharmaceuticals.